candesartan has been researched along with Angor Pectoris in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 9.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 5.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "Candesartan treatment reduced primary end point risk (5." | 2.71 | Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. ( Kondo, J; Kono, T; Kosaka, T; Matsui, H; Morishima, I; Mukawa, H; Murohara, T; Numaguchi, Y; Okumura, K; Sone, T; Tsuboi, H; Uesugi, M; Yoshida, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badar, AA | 1 |
| Perez-Moreno, AC | 1 |
| Hawkins, NM | 1 |
| Brunton, AP | 1 |
| Jhund, PS | 1 |
| Wong, CM | 1 |
| Solomon, SD | 1 |
| Granger, CB | 1 |
| Yusuf, S | 1 |
| Pfeffer, MA | 1 |
| Swedberg, K | 1 |
| Gardner, RS | 1 |
| Petrie, MC | 1 |
| McMurray, JJ | 1 |
| Kasanuki, H | 1 |
| Hagiwara, N | 1 |
| Hosoda, S | 1 |
| Sumiyoshi, T | 1 |
| Honda, T | 1 |
| Haze, K | 1 |
| Nagashima, M | 1 |
| Yamaguchi, J | 1 |
| Origasa, H | 1 |
| Urashima, M | 1 |
| Ogawa, H | 2 |
| Hirai, N | 1 |
| Kawano, H | 1 |
| Yasue, H | 1 |
| Shimomura, H | 1 |
| Miyamoto, S | 1 |
| Soejima, H | 1 |
| Kajiwara, I | 1 |
| Sakamoto, T | 1 |
| Yoshimura, M | 1 |
| Nakamura, H | 1 |
| Yodoi, J | 1 |
| Kondo, J | 1 |
| Sone, T | 1 |
| Tsuboi, H | 1 |
| Mukawa, H | 1 |
| Morishima, I | 1 |
| Uesugi, M | 1 |
| Kono, T | 1 |
| Kosaka, T | 1 |
| Yoshida, T | 1 |
| Numaguchi, Y | 1 |
| Matsui, H | 1 |
| Murohara, T | 1 |
| Okumura, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation[NCT00139386] | Phase 4 | 1,119 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for candesartan and Angor Pectoris